Ennio Tasciotti

Full Professor

Dr. Ennio Tasciotti is a Full Professor of Applied Medical Sciences and Technologies at the Department
of Human Sciences and Promotion of the Quality of Life at the San Raffaele University, and the Founder
and Director of the Human Longevity Program at the IRCCS San Raffaele. He has been included by
Stanford University in the Top 1% of the most influential scientists worldwide for his pioneering
contributions to the field of nanomedicine and for being among the first to exploit the regenerative
power of the immune system to repair tissues and resolve chronic inflammation.

He served as the Chairman of the Department of Nanomedicine (18 faculties, 12 admin staff, 120 researchers), as Founder
and Director of the Center for Biomimetic Medicine at the Houston Methodist Research Institute (15 affiliated faculties,
80 researchers), and as Founder and Director of the Center for Musculoskeletal Regeneration (20 surgeons, 50 research
fellows and residents) at the Houston Methodist Hospital, one of the top 20 hospitals in America. He contributed to 14
technical books, presented at more than 400 conferences worldwide and published over 200 research articles (H-index:
62, over 14.000 citations). His research output has been featured in press releases, scientific and mainstream media,
research outlets, and scientific blogs collectively viewed by over 400 million people. His scientific activity at the intersection
of engineering, pharmacology, biology and medicine resulted in 15 international patents on nanomaterials for biomedical
use, some of which have been licensed to big pharma and private corporations.
Since 2010, he attracted over $15 million of funding from the Department of Defense (DoD) and the Pentagon to create
solutions to repair war wounds, and $10 million from the National Institute of Health (NIH) to develop targeted therapies
for cancer, and $5 million from European funding agencies to test new therapies for neuroinflammation. Dr. Tasciotti
coordinated highly interdisciplinary collaborative research groups in the context of multi-center scientific programs with
leading institutions (Harvard, MIT, Stanford, Northwestern, Rice University), and managed intra- and inter- institutional
research efforts to address today’s unmet clinical challenges. He served as a permanent member of the Texas Medical
Center’s strategic committees for personalized medicine, regenerative medicine, and digital medicine, and assisted in
identifying areas of excellence, critical needs and expansion at the vanguard of applied, translational and clinical research.
As an expert in preclinical and translational research he serves as auditor and reviewer for international think tanks,
working groups, and expert panels for NIH, DoD, the European Research Council (ERC), government agencies and private
institutions in USA, Italy, Israel, Australia, United Kingdom, Austria, France, Netherlands, Switzerland. He participated to
over 40 national and international study sections, evaluated over 1000 scientific and clinical projects and assigned research
funding exceeding $ 1.5 billion. For three years he served as the President of the Italian Ministry of Health Review Panel
for Young Investigators, oversaw the revision of 4,000 proposals and assigned over $ 150 million in grants and projects.
Since 2016 he served on the Advisory Board of the TMCx, the largest incubator in Texas to support the development of
innovative medical technologies. Due to his knowledge of the academic, clinical, and regulatory worlds, he helped linking
scientists to entrepreneurs, financial investments, experts in clinical studies and FDA regulation, and assisted with pilot
studies, tech transfer and licensing of intellectual property. As Scientific Advisor he contributed to the activities of the
Medtronic’s Center for Device Innovation, the Johnson&Johnson hub for the rapid prototyping of medical devices, and the
AT&T Foundry - the only 5G hub for Healthcare in the USA - to identify areas of mutual strategic development.
Dr. Tasciotti is the founder of multiple startups focused on the development of biomedical technologies. In this role, Dr.
Tasciotti coordinates and oversees the design of proof-of-concept studies, the scaling up of manufacturing processes, the
acquisition of Good Laboratory Practices, the definition of Standard Operating Procedures for the experimental settings,
the preparation and submission of regulatory technical files for FDA and EMA. Today he is involved with a multidisciplinary
team of key opinion leaders in the definition of a new concept of Longevity Clinic focused on the cutting-edge advances in
the science of aging and on the state of the art technologies developed to improve quality of life and healthy lifespan.
Dr. Tasciotti serves as a strategic and scientific consultant for national and international companies in the biomedical,
pharmaceutical, digital and food and beverage sectors (Roche Pharma, Novartis, AlfaSigma, Gilead, Corden Pharma, Exact
Sciences, Daichy Sanchio, Aboca, Named, Inpeco, Ushio, Ferrero, Nestlè) as well as scientific advisor for incubators,
accelerators and scientific clusters (Protiviti, G-Factor, ComoNext, Bio4Dreams, Friuli Innovazione, AREA Science Park,
CORIS Veneto, Sclavo Diagnostic International, Cascade Global UK, Technoscience Park, SEC Newgate, Over, EOS
Consulting, Lightscience).
His fields of expertise span from materials for regenerative medicine (including plastic and reconstructive surgery),
pharmacological approaches to drug delivery (targeted and personalized therapies, inflammation and immune
treatments), technologies for nano- and micro-formulations (of pharmaceuticals and nutraceuticals), and digital healthcare
(AI, machine learning and big data). Since January 2023 he serves as Scientific Advisor of The European House Ambrosetti,
and from January 2024 he is the Director of the Scientific Board of Plastic Free. Since 2025 he is the Scientific Director of
Technology Transfer of CubeLabs, the only venture builder in life sciences listed on the EGMPro stock exchange.